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Rhabdomyosarcomais an aggressive childhood malignancy, accounting for more than 50% of all soft-tissue sarcomas in children.
Even with extensive therapy, the survival rate among alveolar rhabdomyosarcoma patients with advanced disease is only 20%.
The receptor tyrosine kinase Epidermal Growth Factor Receptor (EGFR) has been found to be expressed and activated in human
rhabdomyosarcomas. In this study we have used a genetically engineered mouse model for alveolar rhabdomyosarcoma (ARMS)
which faithfully recapitulates the human disease by activating the pathognomicPax3:Fkhr fusion gene and inactivating p53 in the
maturing myoblasts. We have demonstrated that tumors from our mouse model of alveolar rhabdomyosarcoma express EGFR at
both the mRNA and protein levels. We then tested the EGFR inhibitor, Erlotinib, for its eﬃcacy in this mouse model of alveolar
rhabdomyosarcoma. Surprisingly, Erlotinib had no eﬀect on tumor progression, yet mice treated with Erlotinib showed 10–20%
loss of body weight. These results suggest that EGFR might not be an ap r i o r imonotherapy target in alveolar rhabdomyosarcoma.
1.Introduction
Alveolar rhabdomyosarcoma (ARMS) is an aggressive soft-
tissue sarcoma with myogenic features that has a very poor
prognosis in children because of high metastatic potential
and poor response to chemotherapy [1]. The survival rate
for children with metastatic alveolar rhabdomyosarcoma is
dismal even with the tremendous improvements in multi-
modality treatment [2, 3]. Recent studies have shown that
molecularlytargetedtherapiescanbeverysuccessfulintreat-
ing malignant diseases like chronic myelogenous leukemia
(CML)andgastrointestinal stromal tumors[4,5].Epidermal
growth factor receptor (EGFR) is a receptor tyrosine kinase
that has been shown to be expressed or activated in 32–50%
of alveolar and 31–55% of embryonal rhabdomyosarcoma
[6, 7]. Furthermore, the tyrosine-kinase inhibitor Erlotinib
inhibits EGFR and is an FDA approved drug for the treat-
ment of advanced non-small cell lung carcinoma [8, 9]. In
the current study we have tested the preclinical eﬃcacy of
Erlotinib in treating alveolar rhabdomyosarcoma (ARMS)
using a genetically engineered mouse model of ARMS.
2.Methods
2.1. Mice, Drug Administration, and Tumor Monitoring. All
animal procedures were conducted in accordance with the
Guidelines for the Care and Use of Laboratory Animals and
were approved by the Institutional Animal Care and Use
Committee (IACUC) at the University of Texas Health Sci-
enceCenteratSanAntonioand theOregonHealth&Science
University. The Myf6Cre, Pax3:Fkhr, p53 conditional mouse2 Sarcoma
model of alveolar rhabdomyosarcoma has been described
previously [10–12]. Erlotinib was purchased from LC Lab-
oratories (Woburn, MA, USA). Erlotinib was dissolved in
sodium carboxymethylcellulose (0.3% weight/volume) and
Tween 80 (0.1% volume/volume) in saline and administered
at a dose of 100mg/kg once daily by oral gavage for up to
2-3 weeks unless tumor size or the condition of the mice
precluded ongoing treatment.
2.2. MousePrimary TumorCell Cultures. Fresh tumor tissues
from mice were cut into small pieces and suspended in
Dulbecco’s modiﬁed Eagle’s medium (DMEM) containing
collagenase(1mg/mL)at37◦Cfor12hours.Thecollagenase-
containing medium was then removed, and the dissociated
tumor cells were plated in fresh DMEM supplemented
with 10% fetal bovine serum, penicillin (100U/mL), and
streptomycin (100µg/mL; Invitrogen) at 37◦Cw i t h5 %C O 2
in the incubator.
2.3. RT-PCR. RNA was extracted from tumor samples using
TRIzol according to the manufacturer’s instructions (Invit-
rogen, Carlsbad, CA, USA). The Qiagen RNeasy miniprep
cleanupkitwas usedtopurify theextracted RNAas perman-
ufacturer instructions (Qiagen, Valencia, CA, USA). Reverse
transcription using oligodT primers to generate cDNA was
performed as previously described [11]. Real-time PCR was
then performed on an ABI Prism 7500 Fast Real-Time PCR
system using SYBR Green PCR Master mix according to
the manufacturer’s recommendations (Applied Biosystems,
Foster City, CA, USA). Primer sequences for EGFR were
as follows: 5 -CAGATGGATGTCAACCCTGAAG-3  and 5 -
TGGAGAGTGTGTCTTTAAATTCACC-3 .
2.4. Western Blotting. Total protein was extracted from na¨ ıve
andErlotinib-treated primary tumorcellculturesbyhomog-
enization using radioimmunoprecipitation (RIPA) buﬀer
supplemented with phosphatase and protease inhibitors
(Thermo Fisher Scientiﬁc, Waltham, MA, USA). Cell lysates
were then centrifuged at 13,000rpm for 10 minutes, and
supernatant was used for western blot analysis using an
anti-EGFR and anti-phospho-EGFR (Tyr845) antibody (Cat
no. 2232 and no. 2231, Cell Signaling Technology, Beverly,
MA, USA). Appropriate peroxidase-conjugated secondary
antibodies (Vector Laboratories, Burlingame, CA, USA)
were used at 1:5000 dilution. Chemiluminescence was then
detected using SuperSignal West Pico Chemiluminescent
SubstrateorSuperSignalWestDura ExtendedDurationSub-
strate (Pierce Biotechnology, Rockford, IL, USA).
2.5. Histopathology. Histology and Myogenin/Desmin im-
munohistochemistry were performed to aﬃrm diagnosis for
each tumor, as previously described [12].
2.6. Statistical Analysis. The alveolar rhabdomyosarcoma
(ARMS) and skeletal muscle (SKM) groups were contrasted
with regard to the mean Egfr mRNA expression with a t-
test. Erlotinib-treated (n = 13) and untreated control (n =
12) groups were contrasted with regard to the mean tumor
volume (cc), measured repeatedly every 2 days for 19 days or
until death, using a repeated measures linear model with an
autoregressive (1) covariance structure with an adjustment
for day, treatment (Erlotinib versus Control), initial tumor
size (small: <0.4cc, large: >0.4cc), and the treatment by
day interaction. The interaction of day by treatment was
not signiﬁcant and was removed from the model. Weight
was measured repeatedly every 2 days for 15 days or until
death, and treatment groups were contrasted on the mean
weight with a repeated measures linear model with an auto
regressive (1) covariance structure with an adjustment for
day, treatment (Erlotinib versus Control), and the treatment
by day interaction. The day by treatment interaction was not
signiﬁcant and was removed from the model. All statistical
testing was two-sided with a signiﬁcance level of 5% and was
performed with SASVersion 9.2 for Windows (SASInstitute,
Cary, North Carolina).
3.Results
3.1. Although EGFR Is Expressed in Murine aRMS, Erlotinib
Has No Therapeutic Eﬀect. To validate our mouse model
of alveolar rhabdomyosarcoma for the study of EGFR
inhibition, the expression of Egfr mRNA levels in skeletal
muscle and murine tumors was compared using quantitative
RT-PCR. The mean expression (mean±SD) of Egfr mRNA
was signiﬁcantly higherin alveolar rhabdomyosarcoma com-
p a r e dt on o r m a ls k e l e t a lm u s c l e( P<0.001; Figure 1(a)).
Western blot analysis showed stochastic expression of Egfr
protein in 8 of 9 primary tumor cell culture lysates, and
activation (phosphorylation) ofEGFR was observed in 5 of 9
na¨ ıve (untreated) primary tumor cell cultures (Figure 1(b)).
For in vivo EGFR inhibition studies, the structure and purity
of Erlotinib were veriﬁed by mass spectrometry at the pro-
teomicscorefacility oftheUniversityofTexas atSan Antonio
(data not shown). The highest tolerated dose of Erlotinib
was takenfroma priorpreclinicalstudy [13].Tumor-bearing
mice were thus treated with 100mg/Kg Erlotinib daily by
oral gavage. The 13 mice treated with Erlotinib did not
respond to treatment. The Erlotinib and untreated control
groupsdidnotdiﬀersigniﬁcantly with regard tomean tumor
volume (P = 0.21; Figures 2(a) and 2(b)). Mice treated with
Erlotinib experienced a 10–20% loss in body weight with
no corresponding weight change in controls (P = 0.045;
Figure 2(c)). Microsteatosis and vacuolar changes of the
liver were also seen in two Erlotinib-treated mice (data not
shown). No signiﬁcant diﬀerence was found between the
mitotic frequency foruntreated and Erlotinib treated tumors
(Figures 3(a), 3(b),a n d3(c)). Primary cell cultures from
Erlotinib-treated tumors, like untreated tumors, showed
stochastic expression and activation (phosphorylation) of
EGFR (Figure 3(d)).
4.Discussion
Erlotinib (Tarceva) is a highly potent inhibitor of the
tyrosine-kinase receptor Egfr [14]. Erlotinib has been
shown to have single-agent antitumor activity in preclinicalSarcoma 3
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Figure 1: High expression of Egfr in mouse alveolar rhabdomyosarcoma. (a) Quantitative RT-PCR represented as a box and whisker plot
showing expression of Egfr in skeletal muscle and alveolar rhabdomyosarcoma from the mouse model. (b) Western blots showing the
expression and phosphorylation of Egfr in primary cell cultures established from untreated tumors from the mouse model.
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Figure 2: Tumor growth and weight loss in rhabdomyosarcoma-bearing mice treated with Erlotinib. (a) Tumor growth over time in mice
which had tumors smaller than0.4cc at diagnosis.The 50th percentile represents n = 9 control (untreated) tumor-bearing mice. (b) Tumor
growth over time in mice which had tumors larger than 0.4cc at diagnosis.The 50th percentile represents n = 3 control (untreated) tumor-
bearing mice. (c) Animal body weights over the duration of therapy.4 Sarcoma
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Figure 3:Histologicalandbiochemicalanalysisofuntreated andErlotinib-treated tumors.Representative histologyof(a)untreated and(b)
Erlotinib-treated tumors. (c) Mitotic ﬁgures/10 high-power ﬁelds for untreated and Erlotinib-treated mice (P = 0.841). (d) Western blots
showingthe expression and phosphorylation of Egfr in primary tumor cell cultures from Erlotinib-treated mice.
models of non-small cell lung carcinoma, yet when used
in combination with chemotherapeutic agents like cisplatin
or gemcitabine, the antitumor activity was signiﬁcantly
enhanced [9]. Similarly, in a phase III clinical trial involving
patients with advanced pancreatic cancer, when Erlotinib
was administered in combination with gemcitabine, a 23.5%
increase in survival rate was observed compared to patients
who received gemcitabine alone [15].
In our study, surprisingly, Erlotinib had no eﬀect on in
vivo tumor growth despite the presence of EGFR and the
ability of tumors to phosphorylate this receptor tyrosine
kinase. This result suggests thatEgfr might not be an optimal
therapeutic target for single-agent treatment of ARMS. A
possiblelimitationofourstudyisthatErlotinibmaynothave
beenabsorbedwell orally,and hencethedrugmightnothave
reached the tumors at the required concentrations (phar-
macodynamic studies were not performed here). On the
otherhand, atthedosagetested,dose-limited weightloss was
observed.Toxicityatthisdoserangeis consistentwitha Chil-
dren’s Oncology Group Phase I study of Erlotinib with 85–
110mg/kg/day, for which the dose-limiting toxicities were
rash, hyperbilirubinemia, and diarrhea [16]. Another reason
for the lack of activity of Erlotinib may have been that Egfr
might heterodimerize with Her2, raising the possibility that
targeting the Egfr:Her2 heterodimers might be a better ther-
apeutic strategy in alveolar rhabdomyosarcoma. Similarly,
while Egfr homodimers may not play a tumor maintenance
rolein previouslyuntreated alveolarrhabdomyosarcoma, the
possibility remains that refractory (chemotherapy or kinase
inhibitor resistant) tumors may still in fact be driven by
Egfr tyrosine kinase receptor signaling. Taken together, we
suggest that for future Phase II regimens Egfr may still be
a worthwhile target of investigation in the context of com-
bination therapy for refractory alveolar rhabdomyosarcoma-
although, of limited value as monotherapy.
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